Saved in:
Bibliographic Details
Main Authors: Zakhia El Beaino, Célia Dupain, Grégoire Marret, Xavier Paoletti, Laëtitia Fuhrmann, Charlotte Martinat, Yves Allory, Maral Halladjian, Ivan Bièche, Christophe Le Tourneau, Maud Kamal, Anne Vincent‐Salomon
Format: Artículo Open Access
Published: Wiley 2024
Subjects:
Online Access:https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6334
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867017550082080768
author Zakhia El Beaino
Célia Dupain
Grégoire Marret
Xavier Paoletti
Laëtitia Fuhrmann
Charlotte Martinat
Yves Allory
Maral Halladjian
Ivan Bièche
Christophe Le Tourneau
Maud Kamal
Anne Vincent‐Salomon
author_facet Zakhia El Beaino
Célia Dupain
Grégoire Marret
Xavier Paoletti
Laëtitia Fuhrmann
Charlotte Martinat
Yves Allory
Maral Halladjian
Ivan Bièche
Christophe Le Tourneau
Maud Kamal
Anne Vincent‐Salomon
Zakhia El Beaino
Célia Dupain
Grégoire Marret
Xavier Paoletti
Laëtitia Fuhrmann
Charlotte Martinat
Yves Allory
Maral Halladjian
Ivan Bièche
Christophe Le Tourneau
Maud Kamal
Anne Vincent‐Salomon
collection Wiley Open Access
contents Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors Zakhia El Beaino Célia Dupain Grégoire Marret Xavier Paoletti Laëtitia Fuhrmann Charlotte Martinat Yves Allory Maral Halladjian Ivan Bièche Christophe Le Tourneau Maud Kamal Anne Vincent‐Salomon The Journal of Pathology AbstractTumor immunological characterization includes evaluation of tumor‐infiltrating lymphocytes (TILs) and programmed cell death protein ligand‐1 (PD‐L1) expression. This study investigated TIL distribution, its prognostic value, and PD‐L1 expression in metastatic and matched primary tumors (PTs). Specimens from 550 pan‐cancer patients of the SHIVA01 trial (NCT01771458) with available metastatic biopsy and 111 matched PTs were evaluated for TILs and PD‐L1. Combined positive score (CPS), tumor proportion score (TPS), and immune cell (IC) score were determined. TILs and PD‐L1 were assessed according to PT organ of origin, histological subtype, and metastatic biopsy site. We found that TIL distribution in metastases did not vary according to PT organ of origin, histological subtype, or metastatic biopsy site, with a median of 10% (range: 0–70). TILs were decreased in metastases compared to PT (20% [5–60] versus 10% [0–40], p < 0.0001). CPS varied according to histological subtype (p = 0.02) and biopsy site (p < 0.02). TPS varied according to PT organ of origin (p = 0.003), histological subtype (p = 0.0004), and metastatic biopsy site (p = 0.00004). TPS was higher in metastases than in PT (p < 0.0001). TILs in metastases did not correlate with overall survival. In conclusion, metastases harbored fewer TILs than matched PT, regardless of PT organ of origin, histological subtype, and metastatic biopsy site. PD‐L1 expression increased with disease progression. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6334 http://creativecommons.org/licenses/by-nc-nd/4.0/
doi_str_mv 10.1002/path.6334
format Artículo Open Access
id wiley_oa_10_1002_path_6334
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors
Zakhia El Beaino
Célia Dupain
Grégoire Marret
Xavier Paoletti
Laëtitia Fuhrmann
Charlotte Martinat
Yves Allory
Maral Halladjian
Ivan Bièche
Christophe Le Tourneau
Maud Kamal
Anne Vincent‐Salomon
The Journal of Pathology
Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors Zakhia El Beaino Célia Dupain Grégoire Marret Xavier Paoletti Laëtitia Fuhrmann Charlotte Martinat Yves Allory Maral Halladjian Ivan Bièche Christophe Le Tourneau Maud Kamal Anne Vincent‐Salomon The Journal of Pathology AbstractTumor immunological characterization includes evaluation of tumor‐infiltrating lymphocytes (TILs) and programmed cell death protein ligand‐1 (PD‐L1) expression. This study investigated TIL distribution, its prognostic value, and PD‐L1 expression in metastatic and matched primary tumors (PTs). Specimens from 550 pan‐cancer patients of the SHIVA01 trial (NCT01771458) with available metastatic biopsy and 111 matched PTs were evaluated for TILs and PD‐L1. Combined positive score (CPS), tumor proportion score (TPS), and immune cell (IC) score were determined. TILs and PD‐L1 were assessed according to PT organ of origin, histological subtype, and metastatic biopsy site. We found that TIL distribution in metastases did not vary according to PT organ of origin, histological subtype, or metastatic biopsy site, with a median of 10% (range: 0–70). TILs were decreased in metastases compared to PT (20% [5–60] versus 10% [0–40], p < 0.0001). CPS varied according to histological subtype (p = 0.02) and biopsy site (p < 0.02). TPS varied according to PT organ of origin (p = 0.003), histological subtype (p = 0.0004), and metastatic biopsy site (p = 0.00004). TPS was higher in metastases than in PT (p < 0.0001). TILs in metastases did not correlate with overall survival. In conclusion, metastases harbored fewer TILs than matched PT, regardless of PT organ of origin, histological subtype, and metastatic biopsy site. PD‐L1 expression increased with disease progression. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6334 http://creativecommons.org/licenses/by-nc-nd/4.0/
title Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors
topic The Journal of Pathology
url https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6334